<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01794429</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT nr: 2012-005404-17</org_study_id>
    <nct_id>NCT01794429</nct_id>
  </id_info>
  <brief_title>Treatment of Antipsychotic-associated Obesity With a GLP-1 Analogue</brief_title>
  <acronym>TAO</acronym>
  <official_title>Treatment of Antipsychotic-associated Obesity With a GLP-1 Analogue</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bjorn H. Ebdrup</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To examine if 3 months of treatment with a GLP-1 (glucagon-like-peptide-1) analogue can&#xD;
      induce weight loss in obese, non-diabetic patients with a diagnosis within the schizophrenic&#xD;
      spectrum.&#xD;
&#xD;
      The investigators will also examine possible associations between GLP-1 treatment and&#xD;
      peripheral metabolic parameters such as change in body fat and HbA1c. Moreover, the GLP-1&#xD;
      analogue treatment will be associated with the effects/changes on cognition and subjective&#xD;
      quality of life. Possible cerebral effects (pro-cognitive) of the GLP-1 analogue treatment&#xD;
      will associated and correlated with changes in the brain, functional magnetic resonance&#xD;
      imaging (fMRI).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary endpoint is weight loss after 3 months of treatment with the GLP-1 analogue&#xD;
      exenatide (Bydureon®).&#xD;
&#xD;
      Secondary endpoints comprise both physiological/metabolic parameters and cognitive&#xD;
      measurements:&#xD;
&#xD;
        -  Metabolic endpoints include amongst others: changes in body fat (DEXA-scan) and changes&#xD;
           of the HbA1c(average blood glucose levels), cholesterol and triglycerides. Moreover&#xD;
           physiological effects will be examined eg possible effect on central/peripheral&#xD;
           bloodpressure and heart rate.&#xD;
&#xD;
        -  Cerebral endpoints will be investigated via functional magnetic resonance imaging&#xD;
           (fMRI); including potential neuroprotective effects of exenatide. The main focus is&#xD;
           potential hippocampal volume changes and potential changes in cerebral blood flow.&#xD;
           Functional MRI will provide this data and the images will be correlated to both&#xD;
           cognitive tests and questionnaires.&#xD;
&#xD;
        -  Cognitive endpoints comprise potential improvements in cognition with focus on specific&#xD;
           memory tests (BACS, DART and Rey's Complex Figure) and possible improvements in&#xD;
           subjective quality of life (questionnaires).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weight loss</measure>
    <time_frame>3 months</time_frame>
    <description>The primary endpoint is weight loss after 3 months of treatment with a GLP-1 analogue.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effects of GLP-1-analogue treatment on body fat composition</measure>
    <time_frame>3 months</time_frame>
    <description>The investigators will explore potential effects of GLP-1 analogue treatment on different peripheral metabolic parameters: mainly changes in body fat composition (measured by DEXA-scan) and effects on HbA1c, triglycerides and cholesterol.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Obesity</condition>
  <condition>Metabolic Syndrome X</condition>
  <condition>Drug-induced Obesity</condition>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subcutaneum injection of placebo once-weekly for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>exenatide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subcutaneum injection of exenatide once-weekly for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide</intervention_name>
    <description>Subcutaneum injection of exenatide once-weekly for 3 months</description>
    <arm_group_label>exenatide</arm_group_label>
    <other_name>Bydureon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subcutaneum injection of placebo once-weekly for 3 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: 18 - 65 years&#xD;
&#xD;
          -  Diagnosis of the schizophrenia spectrum (ICD-10: F20.x, F25.x)both in-patients and&#xD;
             out-patients will be included&#xD;
&#xD;
          -  Current and unchanged treatment with at least one antipsychotic drug (FGA and/or SGA&#xD;
             and/or depot treatment)&#xD;
&#xD;
          -  BMI ≥30 kg/m2&#xD;
&#xD;
          -  HbA1c &lt; 6,5 %&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Substance dependence (ICD-10: F1x.2 (apart from nicotine addiction F17.2))&#xD;
&#xD;
          -  Diabetes or HbA1c ≥6.5%&#xD;
&#xD;
          -  Contraindications to MRI (metal implants, pacemakers, severe claustrophobia, ≥150 kg&#xD;
             (max. bed weight in the MRI scanner))&#xD;
&#xD;
          -  Previous head trauma with a loss of consciousness for more than 5 minutes&#xD;
&#xD;
          -  Pregnancy (screened by urine human chorionic gonadotropin (hCG),lactation or no&#xD;
             acceptance to use effective contraception during the intervention period&#xD;
&#xD;
          -  Severe somatic disease, including inflammatory bowel disease and chronic ketoacidosis&#xD;
&#xD;
          -  Allergy to exenatide&#xD;
&#xD;
          -  Coercive measures according the Danish Law of Psychiatry&#xD;
&#xD;
          -  conditions that according to sponsor are not congruous with participation in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pelle L Ishøy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Copenhagen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cnsr/Cins</name>
      <address>
        <city>Glostrup</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>February 14, 2013</study_first_submitted>
  <study_first_submitted_qc>February 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2013</study_first_posted>
  <last_update_submitted>June 23, 2015</last_update_submitted>
  <last_update_submitted_qc>June 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Copenhagen</investigator_affiliation>
    <investigator_full_name>Bjorn H. Ebdrup</investigator_full_name>
    <investigator_title>MD PHD</investigator_title>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>The Metabolic Syndrome/disturbances</keyword>
  <keyword>Drug-induced adipositas</keyword>
  <keyword>Schizophrenia</keyword>
  <keyword>GLP-1 analogue</keyword>
  <keyword>cerebral effects</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

